Skip to content

Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations

Comparing the Efficacy of Intravenous Paracetamol and Ketoprofen When Treating Renal Colic in Emergency Situations: a Randomized, Bi-centric, Double-blind Controlled Trial

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01685658
Acronym
PIVKIV
Enrollment
0
Registered
2012-09-14
Start date
2016-09-30
Completion date
2018-03-31
Last updated
2020-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Colic, Acute Renal Colic

Brief summary

The main objective of this study was to demonstrate the non-inferiority of intravenous paracetamol relative to intravenous ketoprofen when treating renal colic in an emergency ward. Efficacy is measured by the change in verbal numeric scale (vns) for pain at 30 minutes.

Detailed description

The secondary objectives of this study are: * To compare the efficacy (non-inferiority) of intravenous paracetamol and ketoprofen at 90 minutes (vns for pain). * To compare both arms in terms of other administered drugs (for pain). * To observe and compare side effects between the two arms: cutaneous manifestation, edema, bronchospasm, nausea, vomiting, headache, palpitation, chest pain, dizziness, disturbance of consciousness, dyspnea, acute retention of urine. * To determine predictors for the use of intravenous morphine when treating renal colic. * To compare hospitalization rates between the two groups. * To compare patient satisfaction concerning care between the two groups (vns for satisfaction) * To observe and compare changes towards complicated renal colic (obstructive pyelonephritis, hyperalgesia, urinary tract rupture, need for surgical drainage, sepsis, death)

Interventions

Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)

Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for a telephone interview at week 1 * Patient consulting at the Nîmes University Hospital emergency ward with suspicion of renal colic

Exclusion criteria

* The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication for a treatment used in this study * The patient has an allergy to ketoprofen or paracetamol, a history of gastric or intestinal ulcers, bleeding disorders, history of asthma triggered by taking ketoprofen or substances with similar activity such as other NSAIDs or aspirin * The patient has a fever or is hemodynamically unstable, oligoanuria * The patient presents with an initial verbal numeric pain score of 10/10. * The patient has a history of aneurysm or aortic dissection, history of renal transplantation, history of renal or hepatic insufficiency * The patient took paracetamol or ketoprofen 4 hours before emergency treatment.

Design outcomes

Primary

MeasureTime frameDescription
Change in vns for painbaseline to 30 minutesVerbal numeric scale ranging from 0 to 10.0.

Secondary

MeasureTime frameDescription
Quantity of (posology) tramadol administeredbaseline (minute 0)
Quantity of (posology) phloroglucinol administeredbaseline (minute 0)
Was morphine administered? yes/nobaseline (minute 0)
Quantity of (posology) morphine administered30 minutes
Quantity of (posology) Nefopam administeredbaseline (minute 0)
Change in vns for painbaseline to 90 minutesVerbal numeric scale ranging from 0 to 10.0.
Presence/absence of complicationsbaseline (minute 0)cutaneous manifestation, edema, bronchospasm, nausea, vomiting, headache, palpitation, chest pain, dizziness, disturbance of consciousness, dyspnea, acute retention of urine
Was the patient hospitalized? yes/nodischarge from emergency ward (estimated max of 24 hours)
VNS for patient satisfaction concerning careweek 1
Evolution towards a complicated renal colicdischarge from emergency ward (estimated max of 24 hours)Qualitative variable with the following classes: obstructive pyelonephritis, hyperalgesia, urinary tract rupture, need for surgical drainage, sepsis, death
Quantity of (posology) Alfuzosine administeredbaseline (minute 0)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026